PolyPid Ltd. (PYPD) |
| 3.75 -0.23 (-5.78%) 07-28 16:00 |
| Open: | 3.77 |
| High: | 3.99 |
| Low: | 3.74 |
| Volume: | 135,917 |
| Market Cap: | 38(M) |
| PE Ratio: | -1.96 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.73 |
| Resistance 1: | 4.94 |
| Pivot price: | 4.72 |
| Support 1: | 3.65 |
| Support 2: | 3.04 |
| 52w High: | 5.73 |
| 52w Low: | 3.06 |
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Financials
| EPS | -1.740 |
| Book Value | 0.460 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -115.1 |
| Return on Equity (ttm) | -758.6 |
Company news
Tue, 28 Jul 2026
PolyPid Ltd (PYPD) Balance Sheet - TradingKey
Mon, 27 Jul 2026
PYPD|PolyPid Ltd|Price:4.240| - TradingKey
Mon, 27 Jul 2026
PYPD|PolyPid Ltd|Price:3.980| - TradingKey
Sat, 25 Jul 2026
PolyPid Ltd (PYPD) Cash Flow - TradingKey
Fri, 24 Jul 2026
PolyPid, Azurity Sign US$330M Deal for D-PLEX100 - Streetwise Reports
Tue, 21 Jul 2026
PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3 - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
